BackCOSCIENS Biopharma Overview

COSCIENS Biopharma Receivables

Track COSCIENS Biopharma's receivables ($2.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$2.78M
↑ 105.39% YoYΔ $1.43M vs prior year quarter

Peer average

Loading

COSCIENS Biopharma Receivables History

Loading

COSCIENS Biopharma vs. peers: Receivables Comparison

Loading

COSCIENS Biopharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

COSCIENS Biopharma (CSCI) FAQ

COSCIENS Biopharma posts a receivables of $2.8M as of June 2025. That compares with $1.4M in the prior-year period — up 105.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, COSCIENS Biopharma's receivables was $1.4M. The latest reading is $2.8M — a 105.4% year-over-year increase (period ending June 2025). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of COSCIENS Biopharma's financial statement story. At $2.8M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CSCI's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; COSCIENS Biopharma's other metric pages and overview cover the third.